⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989392 | 0.68 | CES1 (0.35) | — | |
| SCHEMBL383128 | 0.65 | CES1 (0.37) | — | |
| SCHEMBL18304700 | 0.61 | CES1 (0.37) | — | |
| SCHEMBL2202905 | 0.60 | CES1 (0.52) | — | |
| SCHEMBL3986724 | 0.59 | CES1 (0.44) | — | |
| SCHEMBL29915354 | 0.59 | CES1 (0.71) | — | |
| SCHEMBL206335 | 0.57 | CES1 (0.79) | — | |
| SCHEMBL30448645 | 0.57 | CES1 (1.00) | — | |
| SCHEMBL9673279 | 0.57 | CES1 (0.89) | — | |
| SCHEMBL3872610 | 0.57 | NOS2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228826-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-07-17 | — | — | US | disclosed |
| EP-4504777-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | disclosed |
| US-12133841-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOMED HOLDINGS LTD. (KY) | 2024-11-05 | — | — | US | disclosed |
| US-20240352029-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-10-24 | — | — | US | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023194583-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2023-10-12 | — | — | WO | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023150612-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022143693-A1 | THIENO [2, 3-C] PYRROLE-4-ONE DERIVATIVE | 南京明德新药研发有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |